1.Rudd, et al., Lancet. 2020 Jan 18; 395 (10219): 200-211.
2Torio C, Moore B. “National Inpatient Hospital Costs: The Most Expensive Conditions by Payer.” www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospital-Conditions.pdf, May 2016. Accessed 15 Jan. 2018.
3Seymour CW et al. “Delays from First Medical Contact to Antibiotic Administration for Sepsis.” Crit Care Med 2017; 4595:759–765.
4Whiles BB, Deis AS and Simpson SQ. “Increased Time to Initial Antimicrobial Administration is Associated with Progression to Septic Shock in Severe Sepsis Patients.” Crit Care Med 2017; 45(4):623–629.
5Ljungström L et al. “Diagnostic Accuracy of Procalcitonin, Neutrophil-lymphocyte Count Ratio, C-reactive Protein, and Lactate in Patients with Suspected Bacterial Sepsis.” PLoSONE 2017;12(7): e0181704.
6CDC Vital Signs, August 2016. www.cdc.gov/vitalsigns/pdf/2016-08-vitalsigns.pdf. Accessed 14 Mar. 2019.
7Judd WR, Stephens DM, Kennedy DA. “Clinical and Economic Impact of a Quality Improvement Initiative to Enhance Early Recognition and Treatment of Sepsis.” Ann Pharmacol 2014; 48(10):1269–75.
8Filbin MR et al. “Presenting Symptoms Independently Predict Mortality in Septic Shock: Importance of a Previously Unmeasured Confounder.” Crit Care Med 2018; 46:1592–9.
9 Perman S M, Goyal M and Gaieski, DF. “Initial Emergency Department Diagnosis and Management of Adult Patients with Severe Sepsis and Septic Shock.” Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2012; 20:41. http://doi.org/10.1186/1757-7241-20-41.
10"Drugs of First and Second Choice.” The Medical Letter, 20th ed., 2015; CLSI, M100-ED29:2019 Performance Standards for Antimicrobial Susceptibility Testing, 29th ed.; product Instructions for Use; FDA 510(k) clearances; product recall notices.
11ServiceTrak Clinical Executive Summary Report for ID/AST Systems, 2016.
12Sepsis Alliance. “Fact Sheet. 2018.” Sepsis.org. Accessed 6 Mar. 2019.
*Not available in all countries. Please contact your local Beckman Coulter representative for more information.
MALDI Biotyper is the property of Bruker Daltonik GmbH.
REMISOL Advance is a trademark or registered trademark of Normand-Info SAS in the United States and other countries. Used under license.